EPIX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of ESSA Pharma Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ESSA Pharma Inc. (
NASDAQ: EPIX) to XenoTherapeutics, Inc. is fair to ESSA shareholders.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Monogram Technologies Inc. (Nasdaq - MGRM), Veritex Holdings, Inc. (Nasdaq - VBTX), ESSA Pharma Inc. (Nasdaq - EPIX), Waters Corporation (NYSE - WAT)BALA CYNWYD, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
EPIX Deadline Today: Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of ESSA Pharma Inc. (
NASDAQ: EPIX) securities between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”). The lawsuit describes ESSA as a “clinical stage pharmaceutical company that focuses on the development of small molecular drugs for the treatment of prostate cancer.”
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ESSA Pharma Inc. (“ESSA” or the “Company”) (
NASDAQ: EPIX) and reminds investors of the March 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ESSA Pharma To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ESSA, Cardlytics, Novo Nordisk, and Crocs and Encourages Investors to Contact the FirmNEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of ESSA Pharma Inc. (
NASDAQ:EPIX), Cardlytics, Inc. (
NASDAQ:CDLX), Novo Nordisk A/S (
NYSE:NVO), and Crocs, Inc. (
NASDAQ: CROX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options
EPIX Shareholders Have an Opportunity to Lead the Class Action Against ESSA Pharma Inc. – Contact Shareholder Rights Law Firm Robbins LLP for InformationSAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired ESSA Pharma Inc. (
NASDAQ: EPIX) securities between December 12, 2023 and October 31, 2024. ESSA is a clinical stage pharmaceutical company that focuses on the development of small molecule drugs for the treatment of prostate cancer. The Company's lead product candidate was masofaniten, which was in clinical trial in combination with enzalutamide compared with enzalutamide alone in patients with metastatic CRPC.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ESSA Pharma To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi Reminds ESSA Pharma Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIXFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ESSA Pharma To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ESSA, Cardlytics, Block, and Crocs and Encourages Investors to Contact the FirmNEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of ESSA Pharma Inc. (
NASDAQ:EPIX), Cardlytics, Inc. (
NASDAQ:CDLX), Block, Inc. (
NYSE: SQ), and Crocs, Inc. (
NASDAQ: CROX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ESSA Pharma To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ESSA, IIPR, Block, and Crocs and Encourages Investors to Contact the FirmNEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of ESSA Pharma Inc. (
NASDAQ:EPIX), Innovative Industrial Properties, Inc. (
NYSE:IIPR), Block, Inc. (
NYSE: SQ), and Crocs, Inc. (
NASDAQ: CROX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ESSA Pharma To Contact Him Directly To Discuss Their Options
EPIX STOCK NEWS: EPIX Shareholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Essa Pharma Inc.SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired ESSA Pharma Inc. (
NASDAQ: EPIX) securities between December 12, 2023 and October 31, 2024. ESSA is a clinical stage pharmaceutical company that focuses on the development of small molecule drugs for the treatment of prostate cancer. The Company's lead product candidate was masofaniten, which was in clinical trial in combination with enzalutamide compared with enzalutamide alone in patients with metastatic CRPC.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ESSA, Cardlytics, Block, and Crocs and Encourages Investors to Contact the FirmNEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of ESSA Pharma Inc. (
NASDAQ:EPIX), Cardlytics, Inc. (
NASDAQ:CDLX), Block, Inc. (
NYSE: SQ), and Crocs, Inc. (
NASDAQ: CROX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
EPIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. (“ESSA” or “the Company”) (
NASDAQ: EPIX) and certain of its officers.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ESSA, IIPR, Block, and Crocs and Encourages Investors to Contact the FirmNEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of ESSA Pharma Inc. (
NASDAQ:EPIX), Innovative Industrial Properties, Inc. (
NYSE:IIPR), Block, Inc. (
NYSE: SQ), and Crocs, Inc. (
NASDAQ: CROX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
